

Co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines

Seppic and the Vaccine Formulation Institute (VFI) are moving one step further in their partnership by finalizing the development of their first oil-in-water adjuvant designed for human prophylactic vaccines.

Seppic and VFI are currently finalizing the industrialization at a Seppic plant in France. The product, manufactured under **Good Manufacturing Practices**, will be available in open access for clinical research in the second half of 2020.

Despite outstanding progress in vaccination, **improving access to vaccines** protecting against the most common and serious diseases is a **global health priority**. Guaranteeing **availability of safe and effective adjuvants to all vaccine developers** is a concrete action to face this major challenge.

For more than 25 years, Seppic has been committed to improving global health by designing and supplying adapted adjuvant solutions at industrial scale, to all vaccines producers.

Reaffirming their shared commitments, Seppic and VFI combine their expertise to jointly develop their first open access squalene oil-in-water adjuvant for prophylactic human vaccines. Oil-in-water adjuvant systems are already used in **life-saving vaccines** with demonstrated safety and efficacy profiles. They are promising for **various prophylactic vaccine applications**, including seasonal and pandemic influenza vaccines.

Francois Bertrand, who leads Seppic's adjuvant activities said: *"This co-development illustrates our commitment to bring a ready-to-use adjuvant to the vaccine community. We strongly believe this will accelerate the development of new prophylactic human vaccines and will contribute to a healthier future, everywhere and for everyone".*

Nicolas Collin and Patrice Dubois, Directors of VFI, said: *"Adjuvants are essential components of modern vaccines. However getting access to GMP grade adjuvants has been an ongoing challenge for the vaccine community. We are excited that this co-development will enable for the first time the vaccine community to openly access an oil-in-water adjuvant suitable for use with human prophylactic vaccines".*

Seppic in brief

A company of Air Liquide Healthcare, Seppic designs and markets a wide range of **specialty ingredients for health and beauty**. Present in **100 countries** through its subsidiaries and its network of distributors, Seppic employs **770 people** worldwide, including **110 employees dedicated to innovation**. www.seppic.com

Air Liquide Healthcare

Supplies **medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients**.

In 2019, it served over **15,000 hospitals and clinics** and more than **1.7 million patients** at home throughout the world. The Group's Healthcare business reached **€3,693 million in revenues in 2019**, with the support of its **16,500 employees**.

VFI in brief

VFI is a not-for-profit organization created in 2012. VFI's mission is to facilitate access to adjuvant technologies for the benefit of the global vaccine community, through provision of adjuvants, R&D on vaccine formulations, and training. VFI is a partner in several global vaccine development consortia and programmes, contributing to global health with a specific focus on resource-constrained countries.



MEDIA CONTACTS

Seppic Communications

Alexandra Gilbert
+33 (0)1 42 91 41 18

FP2COM for Seppic

Florence Portejoie
+33 (0)6 07 76 82 83

A world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with approximately 67,000 employees and serves more than 3.7 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide's scientific territory and have been at the core of the company's activities since its creation in 1902.

Air Liquide's ambition is to be a leader in its industry, deliver long term performance and contribute to sustainability. The company's customer-centric transformation strategy aims at profitable, regular and responsible growth over the long term. It relies on operational excellence, selective investments, open innovation and a network organization implemented by the Group worldwide. Through the commitment and inventiveness of its people, Air Liquide leverages energy and environment transition, changes in healthcare and digitization, and delivers greater value to all its stakeholders.

Air Liquide's revenue amounted to 22 billion euros in 2019 and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indexes.

www.seppic.com

Follow us [Twitter](#) and [LinkedIn](#)